Q-omics provides the consensus-scored HEXIM2 profile across patient tissues and cancer cell-line models. HEXIM2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HEXIM2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, HEXIM2 RNA expression shows 20,791 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where HEXIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEXIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEXIM2 survival associations across molecular data types. HEXIM2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEXIM2 RNA expression–survival associations across cancer types. High HEXIM2 expression shows unfavorable associations in UVM and ACC, but favorable associations in HNSC, MESO, BRCA and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for HEXIM2 RNA expression.
This table summarizes HEXIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HEXIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEXIM2 shows lower tumor expression in KICH and higher tumor expression in LIHC, CHOL, LUSC, BLCA and LUAD. The KICH box plot shows higher HEXIM2 RNA expression in normal versus tumor tissue (log2 FC = −1.444, t-test p < 0.001).
This table shows molecular features associated with HEXIM2 in patient tissues and cancer cell lines. In patient samples, HEXIM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HEXIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
